Abstract
Ischemic cardiomyopathy (ICM) is characterized by accumulation of p53 causing apoptosis of cardiomyocytes and resulting in upregulation of miRNA (miR)-192, which plays an important role in the development of heart failure after acute myocardial infarction. However, for other cardiomyopathies, miR-192 seems to have minor relevance. We tested in a prospective, observational study comprising 91 patients with diagnosed heart failure (59.3% ICM and 40.7% non-ICM), the hypothesis that miR-192 expression predicts survival in patients with ICM. Median follow-up was 59 months (range: 1–118). While miR-192 expression was significantly associated with age (p = 0.028), log-rank analysis revealed significant association with survival in ICM (p = 0.003) but not in non-ICM (p = 0.6). In ICM, median age at time of death was 84 years in patients with low miR-192 expression but 67 years with high miR-192 expression. Thus, miR-192 expression is associated with survival in ICM and represents a prognostic marker in ischemic heart failure.
Acknowledgements
We thank HGH Braun for excellent help in patient characterization and data acquisition.
Financial & competing interests disclosure
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
No writing assistance was utilized in the production of this manuscript.
Ethical conduct of research
The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations. In addition, for investigations involving human subjects, informed consent has been obtained from the participants involved.